What is the Harmony Biosciences Holdings, Inc. stock price forecast?

Harmony Biosciences Holdings, Inc. is currently trading at $33.83. View real-time AI analysis on Alpha Lenz.

What is Harmony Biosciences Holdings, Inc. insider trading activity?

View the latest insider trading data for Harmony Biosciences Holdings, Inc. on Alpha Lenz.

What is Harmony Biosciences Holdings, Inc.'s P/E ratio?

Harmony Biosciences Holdings, Inc.'s P/E ratio is 12.3.

Harmony Biosciences Holdings, Inc.

NASDAQ · HRMY

$33.83-0.35(-1.02%)Pre-market

Ask about Harmony Biosciences Holdings, Inc.'s future dividend policy...

Alpha Chat Insight

“Harmony Biosciences Holdings, Inc. trades at a P/E of 12.3 (undervalued) with strong ROE of 20.8%. 3Y revenue CAGR of 25.6% highlights clear growth momentum.”

Ask for details →

Company Overview

Harmony Biosciences Holdings, Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative therapies. It primarily focuses on addressing unmet needs in the healthcare sector, specifically targeting disorders that impact the central nervous system. As part of its core operations, the company develops treatments that enhance the quality of life for patients with conditions such as narcolepsy and related neurological disorders. Harmony Biosciences operates by leveraging scientific research and clinical expertise, aiming to translate advances in neuropharmacology into practical medical solutions. The company's market significance lies in its commitment to niche therapeutic areas which often lack comprehensive treatment options, thus playing a crucial role in the healthcare industry. Through strategic partnerships and a focus on patient-centric innovation, Harmony Biosciences contributes to expanding the availability of specialized medical therapies, impacting both individual patients and the broader medical community.

CEODr. Jeffrey M. Dayno M.D.

Websitehttps://www.harmonybiosciences.com

SectorHealthcare

IndustryBiotechnology

Employees268

Company Statistics

FY 2025

Profile

$1.94BMarket Cap

$868.45MRevenue

0.00Shares Out

268Employees

Margins

77.16%Gross

29.37%EBITDA

24.00%Operating

24.76%Pre-Tax

18.27%Net

Valuation

12.26P/E

2.23P/B

2.24EV/Sales

5.32EV/EBITDA

5.59P/FCF

Growth (CAGR)

25.64%Rev 3Yr

40.30%Rev 5Yr

20.15%Op Inc 3Yr

65.12%Op Inc 5Yr

-4.37%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

13.98%ROA

20.75%ROE

20.23%ROIC

Financial Health

$752.50MCash & Cash Equivalents

$-351.09MNet Debt

46.13%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Harmony Biosciences Holdings, Inc. trades at a P/E of 12.3 (undervalued) with strong ROE of 20.8%. 3Y revenue CAGR of 25.6% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Harmony Biosciences Holdings, Inc. (ticker: HRMY) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 268 employees. Market cap is $1.9B.

The current price is $33.83 with a P/E ratio of 12.26x and P/B of 2.24x.

ROE is 20.75% and operating margin is 24.00%. Annual revenue is $868M.